News|Videos|March 11, 2025

CDMO Partnership Reimagined – Novartis Contract Manufacturing

To ensure the development and reliable supply of medicines to patients around the world, pharmaceutical and biotech companies increasingly rely on CDMOs, their capabilities and their output. How do you choose an outsourcing partner that will meet your high expectations, not only in the short term, but throughout the lifetime of your product? Read more here, and watch our video to learn what makes Novartis Contract Manufacturing different.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.